Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Qiagen prices $150M note deal

Research tool supplier Qiagen (FSE:QIA; QGENF) raised $150 million through

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE